Survival and Clinical Progression in Barth Syndrome: Insights From the Barth Syndrome Foundation's Database of 502 Affected Individuals
The largest study of a rare genetic heart disease reveals early childhood as the critical window for intervention, with transplant access saving lives.
The most comprehensive Barth syndrome natural history analysis to date (N=502, >80% global cases) reveals that early childhood is the highest-mortality window driven by heart failure, with heart transplantation and developed-country access as protective factors. These findings define critical intervention windows and highlight global health disparities in an ultra-rare disease that recently gained its first FDA-approved therapy.
What the study was
- Study design
- Longitudinal registry-based survival analysis with up to 11 years follow-up
- Population
- Barth syndrome patients (>80% known global population), all ages, worldwide
- Sample size
- 502
- Category
- Public Health
- Maturity
- Validated
- Journal
- Journal of inherited metabolic disease
Why it surfaced
Definitive natural history dataset for Barth syndrome covering >80% of known global cases; identifies actionable mortality windows; FDA-approved therapy context (elamipretide 2025) makes this timely for clinical practice. Observational design and single rare disease limit score to 7.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.